Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas. / Baptista, Barbara Oliveira; de Souza, Ana Beatriz Lopes; Riccio, Evelyn Kety Pratt; Bianco-Junior, Cesare; Totino, Paulo Renato Rivas; Martins da Silva, João Hermínio; Theisen, Michael; Singh, Susheel Kumar; Amoah, Linda Eva; Ribeiro-Alves, Marcelo; Souza, Rodrigo Medeiros; Lima-Junior, Josué Costa; Daniel-Ribeiro, Cláudio Tadeu; Pratt-Riccio, Lilian Rose.

In: Malaria Journal, Vol. 21, 2022, p. 6.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Baptista, BO, de Souza, ABL, Riccio, EKP, Bianco-Junior, C, Totino, PRR, Martins da Silva, JH, Theisen, M, Singh, SK, Amoah, LE, Ribeiro-Alves, M, Souza, RM, Lima-Junior, JC, Daniel-Ribeiro, CT & Pratt-Riccio, LR 2022, 'Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas', Malaria Journal, vol. 21, pp. 6. https://doi.org/10.1186/s12936-021-04020-6

APA

Baptista, B. O., de Souza, A. B. L., Riccio, E. K. P., Bianco-Junior, C., Totino, P. R. R., Martins da Silva, J. H., Theisen, M., Singh, S. K., Amoah, L. E., Ribeiro-Alves, M., Souza, R. M., Lima-Junior, J. C., Daniel-Ribeiro, C. T., & Pratt-Riccio, L. R. (2022). Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas. Malaria Journal, 21, 6. https://doi.org/10.1186/s12936-021-04020-6

Vancouver

Baptista BO, de Souza ABL, Riccio EKP, Bianco-Junior C, Totino PRR, Martins da Silva JH et al. Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas. Malaria Journal. 2022;21:6. https://doi.org/10.1186/s12936-021-04020-6

Author

Baptista, Barbara Oliveira ; de Souza, Ana Beatriz Lopes ; Riccio, Evelyn Kety Pratt ; Bianco-Junior, Cesare ; Totino, Paulo Renato Rivas ; Martins da Silva, João Hermínio ; Theisen, Michael ; Singh, Susheel Kumar ; Amoah, Linda Eva ; Ribeiro-Alves, Marcelo ; Souza, Rodrigo Medeiros ; Lima-Junior, Josué Costa ; Daniel-Ribeiro, Cláudio Tadeu ; Pratt-Riccio, Lilian Rose. / Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas. In: Malaria Journal. 2022 ; Vol. 21. pp. 6.

Bibtex

@article{872d739a8a394c75851969ca07ff6c71,
title = "Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas",
abstract = "BACKGROUND: The GMZ2.6c malaria vaccine candidate is a multi-stage Plasmodium falciparum chimeric protein which contains a fragment of the sexual-stage Pfs48/45-6C protein genetically fused to GMZ2, a fusion protein of GLURP and MSP-3, that has been shown to be well tolerated, safe and immunogenic in clinical trials performed in a malaria-endemic area of Africa. However, there is no data available on the antigenicity or immunogenicity of GMZ2.6c in humans. Considering that circulating parasites can be genetically distinct in different malaria-endemic areas and that host genetic factors can influence the immune response to vaccine antigens, it is important to verify the antigenicity, immunogenicity and the possibility of associated protection in individuals living in malaria-endemic areas with different epidemiological scenarios. Herein, the profile of antibody response against GMZ2.6c and its components (MSP-3, GLURP and Pfs48/45) in residents of the Brazilian Amazon naturally exposed to malaria, in areas with different levels of transmission, was evaluated.METHODS: This study was performed using serum samples from 352 individuals from Cruzeiro do Sul and M{\^a}ncio Lima, in the state of Acre, and Guajar{\'a}, in the state of Amazonas. Specific IgG, IgM, IgA and IgE antibodies and IgG subclasses were detected by Enzyme-Linked Immunosorbent Assay.RESULTS: The results showed that GMZ2.6c protein was widely recognized by naturally acquired antibodies from individuals of the Brazilian endemic areas with different levels of transmission. The higher prevalence of individuals with antibodies against GMZ2.6c when compared to its individual components may suggest an additive effect of GLURP, MSP-3, and Pfs48/45 when inserted in a same construct. Furthermore, naturally malaria-exposed individuals predominantly had IgG1 and IgG3 cytophilic anti-GMZ2.6c antibodies, an important fact considering that the acquisition of anti-malaria protective immunity results from a delicate balance between cytophilic/non-cytophilic antibodies. Interestingly, anti-GMZ2.6c antibodies seem to increase with exposure to malaria infection and may contribute to parasite immunity.CONCLUSIONS: The data showed that GMZ2.6c protein is widely recognized by naturally acquired antibodies from individuals living in malaria-endemic areas in Brazil and that these may contribute to parasite immunity. These data highlight the importance of GMZ2.6c as a candidate for an anti-malarial vaccine.",
author = "Baptista, {Barbara Oliveira} and {de Souza}, {Ana Beatriz Lopes} and Riccio, {Evelyn Kety Pratt} and Cesare Bianco-Junior and Totino, {Paulo Renato Rivas} and {Martins da Silva}, {Jo{\~a}o Herm{\'i}nio} and Michael Theisen and Singh, {Susheel Kumar} and Amoah, {Linda Eva} and Marcelo Ribeiro-Alves and Souza, {Rodrigo Medeiros} and Lima-Junior, {Josu{\'e} Costa} and Daniel-Ribeiro, {Cl{\'a}udio Tadeu} and Pratt-Riccio, {Lilian Rose}",
note = "{\textcopyright} 2021. The Author(s).",
year = "2022",
doi = "10.1186/s12936-021-04020-6",
language = "English",
volume = "21",
pages = "6",
journal = "Malaria Journal",
issn = "1475-2875",
publisher = "BioMed Central",

}

RIS

TY - JOUR

T1 - Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas

AU - Baptista, Barbara Oliveira

AU - de Souza, Ana Beatriz Lopes

AU - Riccio, Evelyn Kety Pratt

AU - Bianco-Junior, Cesare

AU - Totino, Paulo Renato Rivas

AU - Martins da Silva, João Hermínio

AU - Theisen, Michael

AU - Singh, Susheel Kumar

AU - Amoah, Linda Eva

AU - Ribeiro-Alves, Marcelo

AU - Souza, Rodrigo Medeiros

AU - Lima-Junior, Josué Costa

AU - Daniel-Ribeiro, Cláudio Tadeu

AU - Pratt-Riccio, Lilian Rose

N1 - © 2021. The Author(s).

PY - 2022

Y1 - 2022

N2 - BACKGROUND: The GMZ2.6c malaria vaccine candidate is a multi-stage Plasmodium falciparum chimeric protein which contains a fragment of the sexual-stage Pfs48/45-6C protein genetically fused to GMZ2, a fusion protein of GLURP and MSP-3, that has been shown to be well tolerated, safe and immunogenic in clinical trials performed in a malaria-endemic area of Africa. However, there is no data available on the antigenicity or immunogenicity of GMZ2.6c in humans. Considering that circulating parasites can be genetically distinct in different malaria-endemic areas and that host genetic factors can influence the immune response to vaccine antigens, it is important to verify the antigenicity, immunogenicity and the possibility of associated protection in individuals living in malaria-endemic areas with different epidemiological scenarios. Herein, the profile of antibody response against GMZ2.6c and its components (MSP-3, GLURP and Pfs48/45) in residents of the Brazilian Amazon naturally exposed to malaria, in areas with different levels of transmission, was evaluated.METHODS: This study was performed using serum samples from 352 individuals from Cruzeiro do Sul and Mâncio Lima, in the state of Acre, and Guajará, in the state of Amazonas. Specific IgG, IgM, IgA and IgE antibodies and IgG subclasses were detected by Enzyme-Linked Immunosorbent Assay.RESULTS: The results showed that GMZ2.6c protein was widely recognized by naturally acquired antibodies from individuals of the Brazilian endemic areas with different levels of transmission. The higher prevalence of individuals with antibodies against GMZ2.6c when compared to its individual components may suggest an additive effect of GLURP, MSP-3, and Pfs48/45 when inserted in a same construct. Furthermore, naturally malaria-exposed individuals predominantly had IgG1 and IgG3 cytophilic anti-GMZ2.6c antibodies, an important fact considering that the acquisition of anti-malaria protective immunity results from a delicate balance between cytophilic/non-cytophilic antibodies. Interestingly, anti-GMZ2.6c antibodies seem to increase with exposure to malaria infection and may contribute to parasite immunity.CONCLUSIONS: The data showed that GMZ2.6c protein is widely recognized by naturally acquired antibodies from individuals living in malaria-endemic areas in Brazil and that these may contribute to parasite immunity. These data highlight the importance of GMZ2.6c as a candidate for an anti-malarial vaccine.

AB - BACKGROUND: The GMZ2.6c malaria vaccine candidate is a multi-stage Plasmodium falciparum chimeric protein which contains a fragment of the sexual-stage Pfs48/45-6C protein genetically fused to GMZ2, a fusion protein of GLURP and MSP-3, that has been shown to be well tolerated, safe and immunogenic in clinical trials performed in a malaria-endemic area of Africa. However, there is no data available on the antigenicity or immunogenicity of GMZ2.6c in humans. Considering that circulating parasites can be genetically distinct in different malaria-endemic areas and that host genetic factors can influence the immune response to vaccine antigens, it is important to verify the antigenicity, immunogenicity and the possibility of associated protection in individuals living in malaria-endemic areas with different epidemiological scenarios. Herein, the profile of antibody response against GMZ2.6c and its components (MSP-3, GLURP and Pfs48/45) in residents of the Brazilian Amazon naturally exposed to malaria, in areas with different levels of transmission, was evaluated.METHODS: This study was performed using serum samples from 352 individuals from Cruzeiro do Sul and Mâncio Lima, in the state of Acre, and Guajará, in the state of Amazonas. Specific IgG, IgM, IgA and IgE antibodies and IgG subclasses were detected by Enzyme-Linked Immunosorbent Assay.RESULTS: The results showed that GMZ2.6c protein was widely recognized by naturally acquired antibodies from individuals of the Brazilian endemic areas with different levels of transmission. The higher prevalence of individuals with antibodies against GMZ2.6c when compared to its individual components may suggest an additive effect of GLURP, MSP-3, and Pfs48/45 when inserted in a same construct. Furthermore, naturally malaria-exposed individuals predominantly had IgG1 and IgG3 cytophilic anti-GMZ2.6c antibodies, an important fact considering that the acquisition of anti-malaria protective immunity results from a delicate balance between cytophilic/non-cytophilic antibodies. Interestingly, anti-GMZ2.6c antibodies seem to increase with exposure to malaria infection and may contribute to parasite immunity.CONCLUSIONS: The data showed that GMZ2.6c protein is widely recognized by naturally acquired antibodies from individuals living in malaria-endemic areas in Brazil and that these may contribute to parasite immunity. These data highlight the importance of GMZ2.6c as a candidate for an anti-malarial vaccine.

U2 - 10.1186/s12936-021-04020-6

DO - 10.1186/s12936-021-04020-6

M3 - Journal article

C2 - 34983540

VL - 21

SP - 6

JO - Malaria Journal

JF - Malaria Journal

SN - 1475-2875

ER -

ID: 288859609